In a recently published article, Liu et al. orchestrated a comprehensive study design conducted on HCC patients, human liver cell lines HepG2, HEK293T, and Huh-7 cells, cholesterol-driven C57BL/6J NAFLD–HCC mice, liver orthotopic xenograft tumors, and on patient-derived xenograft (PDX) tumors with high expression of SNHG6. Here, SNHG6 is linked to metabolic dysfunction-associated steatotic liver disease.